Aquis Stock Exchange Weekly Highlights 02/09/24
0
Published:
September 2, 2024
Most recent
Incanthera plc announced its audited final results for the year ended 31 March 2024. The Company highlighted the following:
- A commercial deal with the world’s largest health and beauty retailer, AS Watson Group, which has 16,500 stores across Europe and Asia.
- Incanthera’s Skin + CELL skincare range of 5 products will be launched in Europe in September 2024 through AS Watson Group partner, Marionnaud, with further anticipated launch through AS Watson Asian store network soon after.
- An Investment round of £1.1m, generating total gross proceeds of £825k.
Simon Ward, CEO, commented: "This is the year in which we have delivered our promise of a successful commercial deal, that will launch our world-class products onto an international stage at the very highest level.” Read more
Equipmake Holdings PLC announced that it has received an initial order for five Zero Emission Drivetrains (“ZED’s”) from South American bus manufacturer, Agrale S.A. This follows a recent successful trial in Buenos Aires of the MT17.0e zero emissions electric bus featuring Equipmake’s proprietary ZED.
Ian Foley, CEO, said: "We are delighted to receive an initial order from Agrale for five Zero Emission Drivetrains following the successful trial of the pioneering MT17.0e electric bus in Buenos Aires. We have been working with Agrale for six years on the development of zero emission busses for the South American market and this initial order represents the exciting next phase in our expanding relationship." Read more
VSA Capital Group plc and Drakewood Capital Management Limited announced a strategic partnership to support each other across commodities trading, commodity fund management and commodity investment banking and broking. VSA anticipates that the Strategic Partnership, combined with the additional capital subscribed by Drakewood, may allow VSA to attract more junior mining companies as corporate clients, recruit experienced professionals and offer junior mining companies capital for growth opportunities. Read more
Ananda Developments PLC announced its management accounts for the quarter ended 31 July 2024. During this period, the Company has made progress in its Phase II clinical trials investigating Chemotherapy Induced Peripheral Neuropathy and Endometriosis, and has focused mainly on preparing submissions to the ethics board at the MHRA in advance of dosing commencement. Also during the period, Ananda announced the results of the pre-clinical study run in partnership with Robert Gordon University. This trial investigated the use of MRX1, the patent pending CBD-based formulation, in mice with Heart Fibrosis with preserved Ejection Fraction. More research on CBD Therapeutic Potential can be read in Ananda’s recent whitepaper here. Read more
ProBiotix Health Plc announced its unaudited results for the six months ended 30 June 2024. The Company highlighted the following:
- Turnover increased by 84% to £1.01m (2023: £0.55m).
- Gross Profit margin increased by 8% to 56% (2023: 48%).
- Signed agreement with Chinese consumer brand, DanCare, for InstaMelt with the launch scheduled for Q4 2024.
Steen Andersen, CEO, commented: "We are pleased with the performance of the Company for the first six months of the year, and the increasing market opportunity allows the Board to remain confident for our future growth strategy.” Read more
